DEFA14A: Royalty Pharma Amends Purchase Agreement to Include Share Subscription for Sellers

Royalty Pharma plc amends its Membership Interests Purchase Agreement to include a share subscription, allowing sellers to receive Class B ordinary shares in the company.

Summary

• Royalty Pharma plc has amended its Membership Interests Purchase Agreement through Amendment No. 1, dated April 11, 2025.
• The amendment includes Royalty Pharma plc as a party to the Purchase Agreement to enable sellers to subscribe for Class B ordinary shares of the company.
• Sellers will receive Class B ordinary shares equal to the number of non-voting Class E ordinary shares of Royalty Pharma Holdings Ltd. they receive as consideration.
• The sellers will subscribe for these shares at a nominal value of US$0.000001 each, payable in cash at the closing of the transaction.
• The amendment also updates various sections of the Purchase Agreement, including those related to share subscription, closing procedures, representations, and warranties.
• The board of directors of Buyer Parent has determined that it is fair to, and in the best interests of the Buyer for the benefit of its shareholders as a whole and Buyer Parent for the benefit of its shareholders as a whole for each of the Buyer and the Buyer Parent to enter into this Agreement.
• The board of directors of Buyer Parent has approved allotment and issuance of the Buyer Parent B Shares contemplated hereby.
• The board of directors of Buyer Parent has directed that the approval of this Agreement (including the transactions contemplated hereby) be submitted to a vote at a meeting of the shareholders of Buyer Parent, and (v) recommended that the shareholders of Buyer Parent approve this Agreement and approve the transactions hereby on the terms and subject to the conditions set forth in this Agreement.

Sentiment

Score: 7

Explanation: The document indicates a positive development in the ongoing acquisition, with the share subscription likely to align interests and incentivize long-term value creation. However, the reliance on shareholder approval and inherent risks in forward-looking statements temper the overall sentiment.

Positives

• The share subscription aims to align the interests of the sellers with those of Royalty Pharma plc.
• The amendment clarifies various aspects of the original agreement, potentially reducing future disputes.
• The board of directors of Buyer Parent has determined that it is fair to, and in the best interests of the Buyer for the benefit of its shareholders as a whole and Buyer Parent for the benefit of its shareholders as a whole for each of the Buyer and the Buyer Parent to enter into this Agreement.

Risks

• The transaction is subject to shareholder approval, which introduces uncertainty.
• The forward-looking statements are subject to risks, uncertainties, and other variable circumstances that could cause actual results to differ materially.

Future Outlook

The document contains forward-looking statements regarding the benefits of the transaction, including cash savings, enhanced alignment with shareholders, increased investment returns, and improved governance. These statements are subject to risks and uncertainties.

Management Comments

• The board of directors of Buyer Parent has determined that it is fair to, and in the best interests of the Buyer for the benefit of its shareholders as a whole and Buyer Parent for the benefit of its shareholders as a whole for each of the Buyer and the Buyer Parent to enter into this Agreement.

Industry Context

This announcement reflects a strategic move by Royalty Pharma to restructure its ownership and align the interests of key stakeholders through equity participation. This is a common practice in the pharmaceutical royalty space to incentivize long-term value creation.

Comparison to Industry Standards

• Equity participation for sellers is a fairly common practice in M&A deals, especially in the pharmaceutical and biotech industries.
• Comparable companies like Ligand Pharmaceuticals or similar royalty-focused firms often use equity incentives to align interests in acquisitions.
• The nominal subscription price of US$0.000001 per share is standard for these types of transactions, as the real value comes from the overall deal terms and future performance.

Stakeholder Impact

• Shareholders: Potential for enhanced alignment and increased investment returns.
• Sellers: Opportunity to participate in the future growth of Royalty Pharma through equity ownership.

Next Steps

• Shareholder vote to approve the transaction and related matters.
• Closing of the transaction, including the share subscription.
• Filing of the definitive proxy statement with the SEC.

Key Dates

Keywords

Royalty Pharma, Purchase Agreement, Share Subscription, Amendment, Class B Ordinary Shares, Transaction, Sellers